Choose date and time: ×
In the last 7 days
Gilead rescinds request for remdesivir orphan status Outsourcing-Pharma.com17:25 30-Mar-20
Developers request revocation of remdesivir’s ODD for COVID-19 European Pharmaceutical Review16:40 26-Mar-20
1 Safe-Haven Stock for the Near Term The Motley Fool10:43 26-Mar-20
Gilead gets rights for virus treatment Salon.com19:20 25-Mar-20
In the last month
Why Is Everyone Talking About Gilead Sciences? The Motley Fool11:07 18-Mar-20
Maker of HIV medication may be close to finding COVID-19 drug Star Observer (Australia)14:38 14-Mar-20
Gilead reports positive data from GS-6207 trial for HIV Clinical Trials Arena11:03 13-Mar-20
Better Buy: Amgen vs. Gilead Sciences The Motley Fool12:54 9-Mar-20
U.S. Public Health Service Strike Team Helps Treat Patients Infected with COVID-19 in Japan U.S. Department of Health and Human Services (Press Release)21:55 3-Mar-20
Gilead Sciences to buy Forty Seven for $4.9bn Pharmaceutical Technology09:25 3-Mar-20
Gilead To Buy Forty Seven, Cancer Therapy Specialist For $4.9B Competition Policy International23:12 2-Mar-20
Is Gilead Overpaying for Forty Seven? 24/7 Wall St.14:56 2-Mar-20
Gilead to Acquire Forty Seven for $4.9 Billion Business Wire (Press Release)12:03 2-Mar-20
Better Buy: Gilead Sciences vs. Pfizer The Motley Fool19:03 1-Mar-20
view more headlines
30 Mar 17:25

No account? Sign up!

  • Follow your favourite topics
  • Save your publication preferences

Publication filters

Headline Density

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
Sorry, no headlines or news topics were found. Please try different keywords.